Hemoglobin M disease

Source: Wikipedia, the free encyclopedia.
Hemoglobin M disease
UV spectroscopy, DNA sequencing
, etc.
TreatmentNo treatment is required

Hemoglobin M disease is a rare form of hemoglobinopathy, characterized by the presence of hemoglobin M (HbM) and elevated methemoglobin (metHb) level in blood.[1] HbM is an altered form of hemoglobin (Hb) due to point mutation occurring in globin-encoding genes, mostly involving tyrosine substitution for proximal (F8) or distal (E7) histidine residues.[2] HbM variants are inherited as autosomal dominant disorders and have altered oxygen affinity.[3] The pathophysiology of hemoglobin M disease involves heme iron autoxidation promoted by heme pocket structural alteration.[4]

There exists at least 13 HbM variants, such as Boston, Osaka, Saskatoon, etc., named according to their geographical locations of discovery. Different HbM variants may give different signs and symptoms. Major signs include

dyspnea, etc.[2][5] Diagnosis is usually suspected based on cyanosis. Biochemical testing, hemoglobin electrophoresis, ultraviolet-visible wavelength light spectroscopy, and DNA-based globin gene analysis can be used for diagnosis.[2][5][6][7][8][9][10] Hemoglobin M disease is often not life-threatening and there is no known effective treatment.[3][5][10][11][12][13]

Hemoglobin M disease is a

recessive condition.[14]

Pedigree chart of the patient's maternal family showing autosomal dominant inheritance

Signs and Symptoms

neonatal cyanosis caused by gamma-chain variants resolves soon after the disappearance of fetal Hb. Infants with beta-globin variants become cyanotic around 6 months after birth with the completion of the fetal-to-adult Hb switch.[19]

Hemoglobin M disease is usually asymptomatic. However, it may show symptoms such as

dysrhythmia, seizure, delirium, coma, and death (metHb level above 70%).[5]

Pathophysiology

HbM is a rare methemoglobin group inherited in an autosomal dominant manner, resulting from

HBB), or gamma (HBG1, HBG2) globin chains. In most HbM variants, the proximal (F8) or distal (E7) histidine residue is replaced by tyrosine.[2][3] Proximal histidine (F8) is designated as position 87 in the alpha chain and 92 in the beta chain. Distal histidine (E7) is designated as position 58 in the alpha chain and position 63 in the beta chain.[5]

Different HbM Variants

At least 13 HbM variants involving alpha- or beta- or gamma-chains have been reported. Six variants, namely HbM Boston, HbM Iwate, HbM Saskatoon, HbM Hyde Park, HbFM Osaka and HbFM Fort Ripley, manifest proximal (F8) or distal (E7) histidine substitution by tyrosine at position alpha-58, alpha-87, beta-63, beta-92, gamma-63 and gamma-92 respectively. HbM Milwaukee-1 involves

glutamate residue at position beta-67.[10]

Alterations in Oxygen Affinity

Normal hemoglobin structure

Under normal circumstances, the heme iron in ferrous state (Fe2+) is covalently bound to imidazole nitrogen of the proximal histidine (F8), and is able to bind to an oxygen molecule.[5]

Tyrosine substitution renders structural alteration of the heme pocket and promotes spontaneous oxidation of heme iron from its ferrous state to

divalent ferrous iron.[5][20] Stable covalent bond between tyrosine and Fe3+ hinders interaction between ferric iron and oxygen. Inability of ferric heme iron in binding oxygen alters oxygen affinity of ferrous heme iron in the remaining normal subunits, impeding oxygen delivery to body tissues.[8][21][22]

Stabilization of ferric iron is done through various abnormal coordination mechanisms between mutant side chains and ferric iron.[22]

Mechanisms of Different Hemoglobin M Diseases

Deoxygenated T (Tensed) state (low-affinity Hb quaternary structure)

metHb reductases or chemical reduction. In HbM Boston (alpha-58 [E7] His→Tyr), new Tyr (E7) coordination alters the heme plane to disrupt the normal interaction between proximal His (F8) and heme iron. In HbM Iwate (alpha-87 [F8] His→Tyr), tyrosine coordination distorts the heme position. This increases the separation between heme group and helix F within the altered alpha subunits for ferric iron stabilization.[22][24]

Oxygenated R (Relaxed) state (high-affinity Hb quaternary structure)

hexacoordinate iron site where transient protonation of Tyr (E7) prompts enzymatic reduction by metHb reductase.[13][22][24] In HbM Hyde Park (beta-92 [F8] His→Tyr), heme loss and instability with nearby residue reconstruction contribute to its pathophysiology.[22][24][25]

Physiological properties of non-mutant subunits within the mutant Hb tetramer differ. Normal alpha subunits in beta-chain variants (HbM Saskatoon and HbM Hyde Park) exhibit significant cooperativity and Bohr effect, displaying an increased oxygen affinity. Normal beta subunits in alpha-chain variants (HbM Boston and HbM Iwate) exhibit reduced cooperativity and Bohr effect, displaying a decreased oxygen affinity. Hence, lower circulating oxidized Hb is observed in beta-chain variants than that in alpha-chain variants.[22][24][25]

For HbM Milwaukee-1 (beta-67 [E11] Val→Glu), proximity of anionic glutamate to the heme iron favors the autoxidation of ferrous iron and stabilization of ferric iron by direct coordination to its sixth coordinate position. This decreases oxygen affinity.[22][26]

Diagnosis

Cyanosis caused by hemoglobin M disease is often mistaken as cardiac or pulmonary defects. Correct diagnosis is important to prevent unnecessary invasive procedures such as cardiac catheterization and mechanical ventilation.[5][22]

Biochemical Testing

Exposure of venous blood samples to pure oxygen can be used to differentiate cyanosis caused by metHb from cardiopulmonary cyanosis or other cyanosis caused by low-O2 affinity Hbs. Cyanotic patients with methemoglobinemia display brownish blood while purple

oxyhemoglobin in other cases.[10] Addition of potassium cyanide (KCN) can be used to further distinguish hemoglobin M disease from other subtypes of methemoglobinemia and sulfhemoglobinemia. For sulfhemoglobinemia, sulfHb is inert to cyanide and shows no colour change. Hemolysates containing metHb with wild-type globin chains turn red immediately. The color change in hemolysates containing metHb with mutated globin chains is slower and the conversion rate for different HbM variants may vary.[22]

Hemoglobin Electrophoresis

Differences in skin colors and arterial blood colors between a normal individual and patients

It provides qualitative analysis by identification of abnormal Hb variants. Addition of KCN before electrophoresis converts all Hb types into metHb to prevent result misinterpretation due to iron state differences. Normal and abnormal Hb variants are separated by electric current, and the observed differences in migration indicate the substitution of the amino acid.[22] For clear separation, hemoglobin electrophoresis should be performed on agar gel at pH 7.1. Under alkaline conditions, HbM migrates slightly slower than HbA.[3] Further confirmatory testing can be performed by high-performance liquid chromatography (HPLC) to provide quantification of the Hb fractions.[6][7][8]

Ultraviolet-Visible Wavelength Light Spectroscopy

Spectral absorption of the hemolysate at various wavelengths can be used for diagnosis.

CO-oximetry using multiple wavelengths is preferred over pulse oximetry in metHb detection. Pulse oximetry only uses two distinct wavelengths of 660 and 940 nm which can be misleading.[12][13]

DNA-Based Globin Gene Analysis

Automated fluorescence-based DNA sequence analysis is applied in the routine diagnosis of hemoglobinopathies as it provides a rapid and reliable result for the identification of specific globin gene mutations.[9] It is used as a further confirmatory test.[8][22]

Treatment

Hemoglobin M disease is often not life-threatening and treatment is not necessary. There is no existing effective treatment, including

oxidant and it is not used to treat hemoglobin M disease. They are prone to develop symptomatic methemoglobinemia given further exposure to oxidants.[13]

References

  1. ^ "Hemoglobin M disease (Concept Id: C3665425) – MedGen – NCBI". www.ncbi.nlm.nih.gov. Retrieved 2022-03-28.
  2. ^
    PMID 30726002
    , retrieved 2022-03-28
  3. ^
    ISBN 978-0-323-53045-3
    , retrieved 2022-03-28
  4. S2CID 26848356
    – via PubMed.
  5. ^
    S2CID 237377613
    .
  6. ^
    S2CID 201115221
    .
  7. ^
    ISBN 978-0-7020-6956-7
    , retrieved 2022-03-28
  8. ^
    ISBN 9780470987001
    .
  9. ^
    S2CID 31589532
    .
  10. ^
    ISBN 978-0-12-383834-6
    , retrieved 2022-03-28
  11. PMID 11527852
    .
  12. ^
    PMID 24872659
    .
  13. ^
    S2CID 244346360
    .
  14. S2CID 36408296
    .
  15. PMID 4625305
    .
  16. S2CID 235362094
    .
  17. PMID 13665153
    .
  18. PMID 32747614
    .
  19. OCLC 1096283151.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link
    )
  20. S2CID 46308991
    .
  21. PMID 7383714
    .
  22. ^
    OCLC 894113533.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link
    )
  23. ^
    PMID 11259676
    .
  24. ^
    PMID 23388674
    .
  25. ^
    PMID 33251782
    .
  26. PMID 16571987
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hemoglobin_M_disease&oldid=1193272971"